ArticleOncotarget2016

Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.

Mahesh Tambe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.